QIAGEN N.V. (QGEN)

QGEN Company Overview & Description 

QIAGEN N.V. is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA, and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analysis. 

We have developed and market more than 500 consumable products and automated solutions. The company provides these products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. 

QIAGEN employs more than 3,800 people in over 35 locations worldwide. 

QIAGEN was founded 1984 as a spin-off at the University of Düsseldorf. Since then the company has continuously developed and turned into what is today the world's leading provider for innovative sample and assay technologies for research in molecular diagnostics, applied testing, pharma and academic research. 

Milestones:  http://www.qiagen.com/about/whoweare/history.aspx 



QGEN Key Company Management 

Peer M. Schatz Managing Director, Chief Executive Officer, has spearheaded the development of QIAGEN's strategic focus on sample and assay technologies and the efforts to bring these technologies to customers in molecular diagnostics, applied testing, academia and the pharmaceutical industry. Mr. Schatz joined QIAGEN in 1993, when the company had just 30 employees and revenues of approximately $2 million. Under his direction, QIAGEN has grown to employ more than 3,700 people in over 35 locations around the world and boasts revenues of more than US$ 1 billion. He has also led QIAGEN to listings on the NASDAQ, making QIAGEN the first German company to do so, as well as the Frankfurt Stock Exchange. Mr. Schatz, a Swiss and Austrian citizen, was born in New York and grew up in the United States and Switzerland. He studied business and social sciences at the University of St. Gallen, Switzerland, where he graduated with a Masters in Finance in 1989. He later obtained a Masters of Business Administration (MBA) from the University of Chicago Graduate School in Business in 1990. Prior to 1993, Mr. Schatz held various positions at Sandoz AG and Computerland and participated in the foundation of startup companies in the computer and software trading industry in both Europe and the United States. He is a member of the German Corporate Governance Commission. He also serves as a member of the Managing Board of PMS Asset Management GmbH and holds director positions of AdvaMedDx (Unites States In-Vitro diagnostics industry organization) and ALSSA (United States Analytical & Life Science Systems Associaton). 

Roland Sackers (born 1968) is Chief Financial Officer and Managing Director of QIAGEN N.V. In this role, Mr. Sackers heads the creation and execution of a long-term financial plan which enables the Company to execute its accelerated growth strategy. 
This roadmap includes numerous M&A transactions, which Sackers enabled and supported through financing activities both on the equity and the debt capital side valued at more than $2 billion. It has led to strong revenue streams and significant profit growth under his tenure. 

Mr. Sackers has earned a degree as Diplom-Kaufmann from the Westfälische Wilhelms-Universität Münster, Germany. He joined the company in 1999 and has been Chief Financial Officer since 2004. In 2006, Mr. Sackers was named Managing Director. Prior to joining QIAGEN, he acted as an auditor with Arthur Andersen. 

Roland Sackers is a board member of the industry association BIO Deutschland and QIAGEN's representative on the Board of Eurofins Genomics B.V. He is also a Non-Executive Director and Chair of the Audit Committee of Immunodiagnostic Systems Holding (IDS), a leading producer of immunological tests for research and diagnostic applications publicly listed in the United Kingdom, as well as Member of the Board and Head of the Audit Committee of Ipsogen S.A., a global leader in molecular profiling and personalized healthcare diagnostics publicly listed in France 

View the complete executive committee: 
http://www.qiagen.com/about/whoweare/management/default.aspx 



QGEN Contact Info 

Qiagen NV 
Spoorstraat 50 
Venlo, 5911 KJ 
Netherlands 
Phone: 31 77 320 8400 
Fax: 31 77 320 8409 
Website:  http://www1.qiagen.com 

Business & Technology 
Dr. Helmut Hilbert 
QIAGEN GmbH 
QIAGEN Strasse 1 
40724 Hilden, Germany 
Tel: +49 (0)2103-29-16221 
Fax: +49 (0)2103-29-26221 
E-mail: bd@qiagen.com 

Investor Relations 
For more information about QIAGEN's business activities, send an e-mail to IR@QIAGEN.com or call +49 (2103) 29-11710 and ask for Investor Relations. 
QIAGEN GmbH 
QIAGEN Strasse 1 
40724 Hilden, Germany 
Phone: +49 (2103) 29-11710 
Email: IR@QIAGEN.com 

View full contact info: 
http://www.qiagen.com/contact/default.aspx?WT.svl=m 

 

Address:
27220 Turnberry Lane 
Suite 200 
Valencia, CA 91355 

Hours: Normal business hours are 6:00 a.m. - 5:00 p.m. (PST) weekdays. 

Telephone:
Technical Service: 800-DNA-PREP (800-362-7737) 
Customer Care: 800-426-8157 


QGEN Recent Developments 
SEC Filings 
http://www.qiagen.com/about/investorrelation/financialinformation/financialreports.aspx 
Competitors 
http://finance.yahoo.com/q/co?s=QGEN+Competitors 
Industry 
http://finance.yahoo.com/q/in?s=QGEN+Industry 
Headlines 
http://finance.yahoo.com/q/h?s=QGEN+Headlines 
Ownership 
http://quotes.barrons.com/QGEN/ownership 



QGEN Products & Services 


Product Brochure:  http://www.qiagen.com/pdfcatalog/ebook/pg_na/default.aspx 


Financial Reporting/Disclosure & Security Details 

QGEN follows under these quidelines on the Nasdaq information market tier and Frankfurt tier under the symbol Frankfurt , Prime Standard: QIA 

Investigate more @  http://www.otcmarkets.com/stock/QGEN/quote for more due diligence. 

Under Dutch law, a company can issue shares up to its authorized share capital provided for in its articles of association, which authorized share capital cannot be more than five times the issued share capital. 

Share Structure 
Market Value1: 3.53B 
Shares Outstanding: 234.12M 
Float: 226.17M 
Common Shares, 0.01 EUR par value, authorized-410,000 shares, issued and outstanding-234,118 and 233,115 shares in 2011 and 2010, respectively 

Transfer Agent(s) 
American Stock Transfer & Trust Company 
Operations Center 
6201 15 th Avenue 
Brooklyn, NY 11219 
Shareholder Services: Phone: +1 (718) 921-8124 
Restricted Share Transfers: Phone: +1 (718) 921-8257 

Financial Reporting/Disclosure 
Reporting Status: U.S. Registered & Reporting: SEC Filer 
Audited Financials: 6k filier 
CIK: 0001015820 
Fiscal Year End: 12/31 
OTC Market Tier: Nasdaq/Frankfurt 

Profile Data 
SIC - Industry Classification: # 2836 
Business Status Development Stage Company: HealthCare/Services 
Research Services 
Incorporated In: Venlo, the Netherlands 
Founded: 1986 
Employees: 3,800 

Security Notes 
New & Secondary Issue=6-96 3,350,000 shs at $12 by Goldman, Sachs & Co. et al 
Capital Change=shs increased by 4 for 1 split. Ex-date=07/14/2000. Rec date=07/03/2000. Pay date=07/13/2000 

OTC Disclosure last 10Q reported on a 6K Nov 14, 2011 period ending Sept 30, 2011 

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8243561 

http://www.qiagen.com/about/investorrelation/aboupdf/qgen_6k_q311_db.pdf 


Before You Invest - Investigate! Always do your own due diligence 

A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing. 

Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy. 

Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, QGEN website